Biogen Idec
NASDAQ : BIIB

Biogen Idec

October 04, 2005 08:59 ET

Biogen Idec Names Naseem Amin, M.D. as Senior Vice President, Business Development

CAMBRIDGE, Mass. and SAN DIEGO--(CCNMatthews - Oct 4, 2005) -

Biogen Idec (NASDAQ: BIIB) today announced that Naseem Amin, M.D. has been appointed Senior Vice President, Business Development. In this role, Dr. Amin is responsible for identifying, executing and integrating transactions derived from external growth opportunities. He reports to Mark Wiggins, Executive Vice President, Business Development.

"Naseem brings proven expertise and a record of success to this important position," said Mr. Wiggins. "Having allocated significant resources to business development, it is vital to execute on our ambitious plan for long-term growth. We are pleased that Naseem has joined us and are confident that his knowledge of business development and leadership will be instrumental as we forge successful partnerships and innovative collaborations."

Dr. Amin joins Biogen Idec from Genzyme Corporation, where he developed a successful track record of identifying and completing partnerships and acquisitions. He most recently served as Head of International Commercial Development. In this position, he had broad responsibility for guiding business development activities in international markets. Dr. Amin also served as Genzyme's Vice President of Business Development and Vice President of Clinical Research. Before joining Genzyme in 1999, Dr. Amin was employed with Baxter Healthcare for seven years where he served as Director of Product Planning and Analysis and in various product management positions.

Dr. Amin has a B.Sc. in biochemistry and an M.D. from Royal Free and University College Medical School at the University of London. He holds an M.B.A. from the Kellogg School of Management, Northwestern University. Dr Amin undertook research in lipid metabolism as a Medical Research Council Fellow at the University of London and Columbia University.

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labelling, press releases and additional information about the company, please visit www.biogenidec.com.

Contact Information

  • Biogen Idec
    Media Contact:
    Jose Juves, 617-914-6524
    Associate Director, Public Affairs
    or
    Investor Contact:
    Oscar Velastegui, 617-679-2812
    Senior Manager, Investor Relations